Healthcare company Trellus Health plc (AIM: TRLS) announced on Wednesday that it has signed a 12-month contract with one of the world's largest Clinical Research Organisations (CROs) to support recruitment and enrollment optimisation for a mid-stage immunology and inflammation clinical trial. The agreement, which begins later this year, follows the company's announcement of advanced contracting discussions and marks a key step in expanding its presence in the clinical trials sector.

The deal includes an upfront fee, monthly management fee and milestone payments linked to three key performance indicators: participant opt-ins to the Trellus TrialSet programme, increased referrals for screening and reduced screen failure rates. Trellus TrialSet leverages the company's proprietary resilience methodology, behavioural science and personalised engagement tools to improve participant readiness, recruitment efficiency, and retention while reducing trial costs.

Trellus Health has also been granted preferred vendor status by a second major global CRO, providing direct access to its client base and accelerating procurement processes for potential future contracts.

Through its Trellus Elevate platform, Trellus Health integrates data analytics with personalised resilience-based care to manage complex chronic conditions such as inflammatory bowel disease (IBD). Clinical outcomes have shown over 90% fewer hospitalisations and more than 70% fewer emergency visits among IBD patients using its approach.

Founded by Icahn School of Medicine at Mount Sinai faculty members Dr Marla C. Dubinsky and Dr Laurie Keefer, Trellus Health continues to broaden its value-based healthcare and clinical trial solutions to improve long-term patient engagement and outcomes.